Eric Dusseux, MD, MSc, MBA
Chief Executive Officer
Prior to joining Bionik, Dr. Dusseux was President of Europe and a director for Auregen BioTherapeutics SA, a 3D bioprinting tissue engineering biotechnology company headquartered in Switzerland, that he formed while at Bemido SA, a family office, with the support of Gurnet Point Capital and Waypoint.
From 2012 through 2016, Dr. Dusseux served as an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur, the vaccine division of Sanofi. Among other responsibilities, Dr. Dusseux, Vice-President Corporate Strategy, was responsible for business intelligence, strategic and business planning, and corporate development.
Before joining Sanofi Pasteur, Dr. Dusseux served as Vice-President, MAGE-A3 Medicines Development Leader, within the Immunotherapeutics Business Unit at GSK Biologicals, a division of GlaxoSmithKline, in charge of therapeutic vaccines against cancer.
Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from 2002 to 2007.
Dr. Dusseux is a Medical Doctor, specializing in Public Health. Dr. Dusseux also holds a Master of Science in Physical Chemistry and is a graduate of the French Business School H.E.C. in Paris (MBA, Isa).
Co-Founder and Chief Technology Officer
Mr. Prywata is the co-founder and Chief Technology Officer of Bionik Laboratories. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.
Rich Russo, Jr.
Chief Financial Officer
Mr. Russo Jr. has over 15 years of finance and accounting leadership experience and is a Certified Public Accountant.
From March 2017 through November 2020, Mr. Russo was the Vice President of Finance and United States Chief Financial Officer, of IcarbonX, a privately held digital health management company specialized in artificial intelligence and health data, and a predecessor PatientsLikeMe. While there, he was responsible for, among other things, the merger of three companies, fundraising, and the ultimate dissolution of certain affiliated companies.
From 2007-2016, Mr. Russo held various key leadership roles for Nasdaq-listed companies in life sciences, pharmaceutical and medical device industries. From September 2015 to October 2016, he served as Corporate Controller for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, and prior to that, he had roles at Juniper Pharmaceuticals, a woman’s health company focused on developing therapeutics, and Cynosure, a medical device company focused on aesthetic treatment systems. In each of these roles, Mr. Russo was responsible for all finance activities and SEC reporting, including partnering closely with management to ensure effective and efficient financial procedures throughout the organizations. Mr. Russo started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group.
Mr. Russo is a graduate of Bridgewater State University in Bridgewater, MA, where he graduated from a dual degree program, receiving his Bachelor of Science in Accounting and his Masters in Management and Accounting.
Chief Commercial Officer
From January 2014 through August 2019, Mr. Wass the Vice President of Sales, Business Development and Reimbursement at ReWalk Robotics Ltd. (Nasdaq:RWLK), a medical device company focusing on rehabilitation, and was also a member of its Executive Committee. While at ReWalk, Mr. Wass was responsible for U.S. sales and business development, reimbursement activities and payer policy strategies and submissions. Mr. Wass holds a B.S. from Springfield College.
Malcolm G. Bock
Vice President of Engineering
Mr. Bock previously served as the Vice President of Engineering at Respiratory Motion, where he was responsible for creating a product pipeline and technology roadmap, and bringing the company's first product from concept to launch in 10-months' time. Prior to that, Mr. Bock served as the Senior Director of Global R&D for Covidien Ltd., a spin-off of Tyco International, where he was responsible for R&D and launching 15 new products, including both durable electro-mechanical systems and single-use devices, over a 10-year period. In 2011, he was awarded Covidien Inventor of the Year. Over the course of his career, Mr. Bock has launched over 38 new products and was awarded Best Divisional Vitality Index, and Best New Product for his work at Covidien. He has also been awarded 30 patents, with an additional 28 patents pending.